Expression of CD99 is higher on immature than on mature T cells. We postulated that this marker could be used to assess minimal residual disease (MRD) in T-lineage acute lymphoblastic leukemia (T-ALL). In diagnostic bone marrow (BM) samples from 27 children with T-ALL, expression of CD99 on leukemic lymphoblasts by flow cytometry was in median 7.7 times higher than on normal T lymphocytes from within the same sample. In 85% of cases, leukemic MFI values were higher than the mean MFI þ 2 s.d. of normal populations. We applied CD99 to study MRD in 39 follow-up samples from 15 consecutive T-ALL patients, and compared the results with those obtained with the well-established MRD-marker terminal deoxynucleotidyl transferase (TdT). Either antibody was combined in four-color flow cytometry with CD7, surfaceCD3, and cytoplasmicCD3. We found that CD99 was a valid complement to TdT in quantifying T-ALL MRD. Given a considerable interpatient variability, CD99 could be favorably used in nine patients, and TdT in other five patients. Both approaches showed a similar very low nonspecific background throughout 12 weeks from diagnosis (in median 0.002% of nucleated BM cells in patients with non-T ALL). We conclude that CD99 is a highly informative tool for MRD detection in T-ALL, bearing the advantage of surface expression in contrast to TdT.
Introduction
CD99 is a 32-kDa cell-surface sialoglycoprotein encoded by homologous genes located in the pseudoautosomal regions of both human sex chromosomes. 1, 2 The antigen is broadly expressed on hematopoietic as well as other cell types, 1, [3] [4] [5] but most intensely in the earliest maturational stages of the myeloid and the lymphoid lineages. 3, [6] [7] [8] The observation of strong CD99 expression in thymus and in T-lineage acute lymphoblastic leukemia (T-ALL) dates back already to 1979; 6 however, there are still no comprehensive data on the patterns and variance of expression of this antigen in a larger number of T-ALL cases. Direct correlations with the expression patterns of normal T cells are also lacking. We were therefore stimulated to investigate these issues, and to determine whether CD99 could emerge as a new tool for the detection of minimal residual disease (MRD) in T-ALL. We speculated that normal and leukemic cells could be distinguished in bone marrow (BM) and peripheral blood (PB) based on CD99, since maturationrelated CD99 overexpression should be nonexistent or extremely rare on T cells outside the thymus.
Materials and methods

Leukemia samples
Diagnostic BM samples were obtained from 27 of 30 consecutive pediatric patients with T-ALL enrolled in Austria since 1995 in nationwide treatment programs based on BerlinFrankfurt-Mü nster (BFM) protocols. 9 The median age of the patients (21 male, six female) at diagnosis was 6 years (range 1.5-15 years). A total of 11 patients had a leukemia with a pre-T phenotype, seven had an intermediary, and nine had a mature T-ALL according to BFM criteria. 10 Data concerning routine immunological analyses leading to these subtype classifications were adopted from the Austrian study center of the BFM group. BM investigations were generally approved by the institutional ethical committees, and were carried out according to informed consent guidelines.
Follow-up and control samples
For comparison of the usefulness of CD99 and terminal deoxynucleotidyl transferase (TdT) for MRD detection, we obtained 39 follow-up samples (PB from days 8 and 15, BM from day 15) from 15 of 16 patients with T-ALL of a series of 113 consecutively recruited ALL patients treated with the current ALL-BFM 2000 protocol. The time points very early in treatment were chosen to allow for mostly positive MRD results so that CD99 and TdT could efficiently be compared. Further follow-up BM samples (n ¼ 23) from children with B-cell precursor ALL (17 with common, six with pre-B ALL) served as controls for the specificity of CD99-based MRD investigations. These samples were from four time points (day 15: n ¼ 6; day 33: n ¼ 5; day 52: n ¼ 6; week 12: n ¼ 6) where MRD detection correlates with prognosis.
11
Antibodies, immunofluorescence staining, and flow cytometry The preparation of mononucleated cells (MNC) from BM at diagnosis, and the immunofluorescence staining were conducted as extensively described. 12, 13 Follow-up investigations were based on total nucleated cell preparations (NC) in order to allow also for absolute MRD quantification, 11 and on a two-step cellular permeabilization procedure (Fix & Permt, Caltag Laboratories, Hamburg, Germany). NC were prepared with a commercially available red cell lysis solution (BD). In general, four-color investigations (FITC/PE/PC5/APC) on the basis of fixed combinations of directly labeled MoAbs were performed: CD99/ CD7/surface(s)CD3/cytoplasmic(c)CD3, TdT/CD7/sCD3/cCD3, and CD99/CD7/CD5/sCD3 (surface only). For Analyses were performed on a dual-laser FACSCaliburt (BD). Details regarding the test standardization, the data acquisition with the CELL Questt software (BD), and the data analysis using the PAINT-A-GATEt software (BD) have been delineated.
12,14
Data analysis
In similarity to recently published work, 8, 12 the CELL Questt software (BD) was used to quantify subset-specific antigen expression intensities on gated malignant or normal T-cell populations. In this semiquantitative approach, fluorescence signals on a logarithmic scale were evaluated, and the median fluorescence intensities (MFI) were used for further comparison of antigen densities. A CD99 expression quotient was calculated for each individual diagnostic sample by dividing the MFI value of the leukemia by that of the respective normal T-cell population from within the same sample. The PAINT-A-GATE software (BD) was used to determine the proportions of malignant or physiologic T cells in initial as well as follow-up Figure 1 Discrimination of normal and leukemic T-cell populations in BM by divergent expression of CD3, CD5, CD7, and CD99 at leukemia diagnosis (left) and during follow-up (right). T-ALL blasts are shown in red, all other cells in gray. Note that during follow-up, minute proportions of T-ALL blasts among NC can clearly be visualized and quantified as MRD by their intense CD99 expression.
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BM specimens as well as to visualize marker coexpression patterns as described recently. 11 In order to comparatively estimate the values of CD99 and TdT, MRD quantification was strictly oriented on the expression of either marker, thus excluding possibilities to discriminate MRD based on the other markers in the MoAb combinations used. For control purposes, we quantified also sCD3 neg/dim cCD3 pos events with TdT or high CD99 expression (higher than normal T cells from within the same sample) in follow-up BMs from patients with B-cell precursor ALL. The proportions of these events among 7-10 Â 10 5 stained cells were recorded as background thresholds and served as measures of test specificity.
Statistical analysis
The correlation of CD99 MFI value distributions with T-ALL phenotypic subtypes was determined using the Kruskal-Wallis analysis of variance. Equivalence of background value distributions was investigated using Hodges-Lehmann estimates. Statistical investigations into differences in the amounts of MRD detected with CD99-or TdT-based staining combinations were performed using the w 2 -test including the Yate's correction of continuity as well as the Wilcoxon's signed-rank test.
Results
CD99 in normal and malignant T-cell populations
Normal and leukemic T-cell populations were addressed on the basis of their divergent expression of CD3, CD7, and CD99 (Figure 1 ). In the 27 BM samples from patients at diagnosis, the median blast cell proportion was 71.2% (range 32-93%), and that of residual normal T cells 4.4% (range 0.2-41.4%). T-ALL blasts displayed higher expression of CD99 compared to the respective normal T cells from within the same BM sample in all cases investigated. Importantly, we found that CD99 expression of activated T lymphocytes (CD25 þ or HLA-DR þ ) did not outrange that of the bulk of other normal T cells (data not shown). The expression was quantified by selective gating on individual T-cell populations and subsequent calculation of MFI values. Based on the FITC-labeled MoAb TÜ 12, the median CD99 MFI of T-ALL populations was 103 (range 14-543), and that of normal T cells was 18 (range 7-31) as shown in Figure 2 . Among correlated values from individual samples, the median MFI quotient was 7.7 (range 1.6-28.3). In all, 85% of T-ALLs showed higher MFI values than the mean MFI þ 2 s.d. (ie 31) of all normal T-cell populations, which reflects incomplete separation of leukemic and normal T cells by CD99 in a minor but significant proportion of cases. Such lower CD99 expression, however, did not correlate with general T-ALL differentiation patterns, since we found no significant difference in CD99 expression (P ¼ 0.19 for MFI quotients, and P ¼ 0.68 for leukemic CD99 MFI values) when stratifying by T-ALL subtypes (pre-T, intermediary, mature).
CD99 background during ALL follow-up
As a first step of implementing the CD99-approach to MRD studies in T-ALL, we assessed the specificity of this approach in comparison to the established approach based on the combination TdT/sCD3/cCD3. High CD99 expression on cells with an immature T-cell phenotype (sCD3 dim/neg cCD3 pos ) was rarely found in follow-up BM samples (n ¼ 23) of patients with B-cell precursor ALL. In these samples (Table 1) , the background of the CD99-approach was quantitatively not different from that of the TdT-approach (P ¼ 0.63, 70.007 confidence interval 95%), but significantly lower than the proportions of nonspecific sCD3 dim/ neg cCD3 pos or sCD3 neg cCD3 pos events alone (Po0.001 for both comparisons). Importantly, at individual follow-up time -points, the background values of the CD99-approach were within similar ranges. 
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Figure 2
CD99 antigen expression levels of T-ALL blasts compared to normal T cells. Cell populations were gated for purity and analyzed for antigen expression as reflected by the median fluorescence intensity (MFI, logarithmic scale). Each data point represents the antigen density on the blasts of an individual leukemia sample, on physiologic T cells, or the correlation coefficient (MFI-Q) between the expression levels of T-ALL blasts and accompanying normal T cells from within the same diagnostic sample. Symbols (À) mark the site of the median of the MFI values of a category. Table 1 Background events in control bone marrows 
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Figure 3
Head-to-head comparison of MRD monitoring with CD99 and TdT. PB and BM samples from diagnosis and early follow-up (days 8 and 15) from three patients (a-c) are shown. T-ALL blasts are depicted in black, all other cells in gray. Note that in follow-up samples of patients (a and b), leukemic blasts can be easily detected upon high CD99 expression, whereas TdT patterns do not allow for an unambiguous and comprehensive visualization. By contrast, TdT is the more valuable marker in patient (c). Note that the applicability of either marker depends on phenotypic evolutions rather than on primary antigenic patterns.
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CD99 and MRD detection in T-ALL
As a next step, we compared the usefulness of CD99 and TdT for monitoring MRD based on staining combinations with a common CD7/sCD3/cyCD3 backbone. All investigated 15 consecutive T-ALLs expressed both CD99 and TdT at diagnosis. In total, 39 early follow-up samples from PB (n ¼ 24; days 8 and 15) or BM (n ¼ 15; day 15) were available for paired analysis of MRD. A total of 35 of the samples (90%) were found MRD positive with both markers (median MRD 1.05% of NC, range 0.01-28.6% by CD99; 0.69%, range 0.01-33.3% by TdT), and the remaining four samples were qualified negative by both (three of the latter were from a single patient).
In the 35 MRD-positive samples (from 14 patients), CD99-and TdT-based MRD amounts differed by a median factor of 1.23 (range 0.02-212). We found higher MRD amounts by CD99 assessment in 24 samples (69% of positive) and by TdT in 11 samples (31%). According to this, CD99 was more favorable for MRD detection in nine patients, and TdT was superior in the other five patients. Particularly, large differences in MRD proportions (more than five-fold) were found in 12 sample pairs (34%), including nine samples from five patients with higher CD99-MRD, and three TdT-superior samples from three patients. In 10 of these 12 samples, the differences exceeded even one log-step (including all of the nine CD99-superior samples). This considerable interpatient variance in the usefulness of CD99 and TdT as MRD-detection tools is reflected in Figure 3 . Overall, CD99 proved statistically more useful than TdT in ability to disclose MRD (Po0.05). Interestingly, in two patients, TdT was more useful for assessing MRD in BM than in PB (CD99 was favorable in both materials), but the overall applicability of TdT to PB or BM was not significantly different.
By contrast, comparing the two different CD99 containing MoAb combinations (7permeabilization plus cCD3 or CD5), we found only marginal differences in MRD estimates. Permeabilized samples showed consistently (88% of samples) slightly higher MRD values (median factor of difference 1.55, range 0.8-12), but differences were mostly small. Only three of 26 paired values (12%) differed more than five-fold, and only one of these differed by more than 1-log step.
Discussion
Levy et al 6 described the human thymus-leukemia antigen CD99 for the first time in 1979. They found that CD99 was brightly expressed on cortical thymocytes and at similar intensity by TALLs, whereas normal peripheral blood lymphocytes appeared to exhibit only low levels of the antigen. There were, however, no detailed data reported in their communication on how many individual leukemia samples had been tested, and what is the variance in CD99 expression between different leukemia samples. In the present study, we show now that T-ALL blasts display an in median 7.7 times higher CD99 expression than normal T cells from within the same sample. We also show that although a majority of T-ALLs were distinctly brighter stained with CD99 MoAbs than mature physiologic T cells, a minor but considerable proportion of leukemia cases (15%) was not. Interestingly, this phenomenon of lower CD99 expression in some T-ALLs was not related to leukemic phenotypic subtypes. This could have been surmised from the patterns found in normal thymocyte maturation, where CD99 is downregulated along with increasing expression of CD3 on the cell surface. 3 The observed patterns of CD99 expression prompted us to investigate whether this antigen could be of use for MRD detection. Assessing the MRD load in ALL has recently been shown to bear important prognostic relevance, which is independent from all previously known risk factors including conventional measurement of the therapy response. 11, [15] [16] [17] [18] Hence, detection of MRD may have profound impact on future clinical management strategies in leukemia. In this respect, the phenotypic peculiarities of T-ALLs were among the first to be exploited for MRD monitoring in BM as well as cerebrospinal fluid. [19] [20] [21] [22] [23] In particular, coexpression of TdT and cCD3, a feature normally confined to the thymic T-cell breeding environment, was found to be a reliable and sensitive denominator of T-ALL MRD outside the thymus. The frequency of this 'ectopic' phenotype is high among T-ALLs, 24 and therefore this antigenic combination has been used for MRD monitoring in recent flow cytometric studies. 11, 15, 16 However, we found recently that TdT may not be applicable to all patients with T-ALL. 11 Hence, there is a need for complementary strategies.
We show now that the CD99-approach is a highly reliable and promising candidate in this respect. In our investigation of 15 consecutive T-ALL patients, CD99 was stable and more useful for MRD assessment than TdT in nine patients, whereas TdT was superior to CD99 in other five patients. Owing to phenotypic evolutions under treatment, the usefulness of either marker could not simply be predefined based on the leukemic expression profile at diagnosis. CD99 lacked sensitivity in three patients, and TdT in other five, as reflected by more than threefold differences in correlated MRD estimates. Among samples from these patients, conventional morphology confirmed high residual disease proportions in day 15 BM detected solely by TdT in one sample, and only by CD99 in four. In one of these patients (see Figure 3A) , MRD detected by CD99, but not by TdT, remained high throughout further treatment, and this was the only patient of our cohort who eventually suffered from an early disease relapse, although lacking other high-risk criteria including PCR-based MRD.
A further advantage of CD99 is its cell surface expression. CD99 can thus be combined with CD7, sCD3, and either cCD3 (cellular permeabilization needed) or CD5 (surface only), still giving highly concordant results. By contrast, TdT detection always requires cellular permeabilization, which makes the assay more laborious and prone to complications compared to surface-only staining.
Advantageously, the specificity of the TdT-and the CD99-approach is similar. We found that the level of CD99 high background is stably very low in BM at all recently established time points of prognostic relevance in the early phase of ALL therapy. 11 Suggestively, this is due to the fact that significant Tcell breeding does not occur in BM. This contrasts with the situation in B-lineage ALL, where flow cytometric MRD detection in BM is strongly influenced by regeneration of immature normal precursors.
11
In conclusion, CD99 is a powerful tool for MRD detection in T-ALL and should definitely be used to complement current strategies relying on TdT in order to allow reliable monitoring of most patients. collaboration in providing BM and PB samples. In this respect, we
